Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors

NCT06660654 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT06660654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06660654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 6, 2025
Completion date
December 30, 2029
Enrollment
335 (estimated)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, metastatic solid tumors